Evidence Sheet: Alphabet (GOOGL)
The standing BullScope yardsticks for Alphabet, computed from official filings and refreshed with each new edition.
Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.
The standing BullScope yardsticks for Alphabet, computed from official filings and refreshed with each new edition.
In one breath Chevron's Q2 2026 filing shows a company producing more oil than it ever has on U.S. soil,...
A resilient net margin and a stock sitting near a two-year low. Those two facts should not coexist for a...
For most of the last decade, owning PepsiCo felt like owning a toll road. Revenue climbed steadily, the dividend arrived...
McDonald's has appointed Skye Anderson, a 26-year company veteran, as President of McDonald's USA, effective immediately, replacing Joe Erl
McDonald's reported second-quarter net income of $2,362 million, up 5 percent from $2,253 million a year earlier, with diluted earnings...
The standing BullScope yardsticks for Meta Platforms, computed from official filings and refreshed with each new edition.
In one breath Merck's filed revenue is growing and its newest drugs are landing approvals, but two enormous acquisition charges...
Caterpillar reported second-quarter 2026 sales and revenues of $20.5 billion, a 24% increase from $16.6 billion in the same quarter...
Merck reported a net loss of $5,575 million for the first half of 2026, a reversal from a $9,506 million...
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer